Stock·NYSE·Healthcare
Stryker Corp. (SYK)
- Market cap
- $111.95B
- P/E
- 30.24
- Dividend yield
- 1.21%
- Street target
- $360.00median of 29 analysts
- 52-week range
- $267.00 $389.33
SYK stock forecast today
Where SYK stands today, and what CleaRank Financial AI makes of it.
SYK at a glance
Stryker Corp. (SYK): Hold, 56/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($292.71 and $323.82).
- Earnings SYK beat estimates in 6 of its last 7 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $738.2M and made no open-market purchases over the last 18 months.
- Valuation P/E of 30.2 against 31.9 for the Healthcare sector: broadly in line with peers (-5%).
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates Stryker Corp. (SYK) Hold, with a model score of 56/100.
The analysts' outlook lifts the score most: 23 of 29 analysts rate it a buy and the median target is 23.3% above the price. The trend holds it back most: the price is 9.87% below its 200-day average and 0.29% below its 50-day average, and the 50-day average is 9.61% below the 200-day. The 50-day average stands at $292.71 and the 200-day at $323.82. Over the past year the price fell 20.90%.
Only on CleaRank
Figures we compute ourselves from SYK's own price, earnings and insider-filing history. Tap one to see it in context.
SYK stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price below its 50-day average ›
The price of $291.86 is 0.3% below the 50-day simple moving average of $292.71.Price below its 200-day average ›
The price is 9.9% below the 200-day simple moving average of $323.82.50-day average below the 200-day ›
The 50-day average ($292.71) is 9.6% below the 200-day average ($323.82), the arrangement of a falling longer-term trend.In the lower half of its 52-week range ›
The price sits at 20% of its 52-week range, between $267.00 and $389.33.
SYK share price
Pick a period: each tab shows how far SYK has moved over it, to the last close.
Today's trading
Where SYK sits inside today's range and its 52-week range.
SYK fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 30.24 is 5.2% below the Healthcare median of 31.9.P/S above the sector median ›
The price-to-sales ratio of 4.33 is 27.4% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $3.7B on revenue of $25.8B, a net margin of 14.4%.Beat estimates in most recent reports ›
SYK beat the EPS estimate in 6 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 1.21%, or $3.52 a share a year.
Key statistics
The headline figures for SYK.
As of October 30, 2026, SYK trades at $291.86, with a market value of $111.95B, a P/E ratio of 30.24 and a dividend yield of 1.21%.
What the numbers say
CleaRank Financial AI's reading of SYK's valuation, growth and risks.
SYK's trailing P/E is 30.24, set against a Healthcare median of 31.9. That leaves it 5.2% below the sector median P/E, and the peer comparison on this page rates the P/E as broadly in line with peers. On sales, the P/S of 4.33 stands 27.4% above the sector median of 3.4. The company's market value is $111.9B.
Healthcare peers grew revenue a median 8.1% in the same period, so SYK's 9.40% rise in the latest quarter year on year runs 1.3 percentage points ahead. On profitability, the net margin stands at 14.43% and the operating margin at 27.02%. Return on equity, a measure of what shareholders' capital earns, is 16.51%, above the sector median of 7.3%. Debt-to-equity sits at 0.64, and the trailing dividend yield is 1.21%, equal to $3.52 a share each year.
In its latest quarterly report, on July 30, 2026, SYK posted $3.69 a share against a $3.49 estimate, coming in above the estimate by 5.73%. Even so, the share price fell 6.42% in the first session after the report.
SYK beat the EPS estimate in 6 of its last 7 reports; even so, 4 of those 6 beats were followed by a lower share price the next session. Of the 3 reports before the latest, the largest reaction came after the April 30, 2026 report, which missed the estimate by 12.75% while the stock fell 6.47%. Analysts' average EPS estimate for this fiscal year is $14.95, which would be growth of 9.7%, and $16.66 for next year (growth of 11.4%).
Day-to-day volatility is the first thing to plan around: SYK has moved 2.03% on an average session with a beta of 0.78 against the S&P 500. The downtrend is itself a risk for as long as the price stays under both moving averages. The price is 25.04% below its 52-week high of $389.33. Over the last 18 months, insider sales totalled $738.2M with no open-market purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
SYK against the Healthcare sector
How SYK compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-5% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 20, 2025, SYK has lost 25.1% against a gain of 37.3% for XLV.
Performance against XLV
SYK and the Healthcare sector fund over the same days.
Revenue and earnings
How much SYK sells, and how much of it becomes profit.
Revenue growth: Revenue grew 11.2% in FY2025 to $25.1B, from $22.6B a year earlier.
Profit margin: The net margin was 12.9% in FY2025, down from 13.2% the year before.
Profitable: SYK earned $3.2B in FY2025.
Earnings reality check
Did SYK beat what analysts expected, and how did the stock react?
Earnings record: SYK beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 4 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $3.49 | $3.69 | +5.73% | -6.42% | -3.05% |
| Apr 30, 2026after close | $2.98 | $2.60 | -12.75% | -6.47% | -6.63% |
| Jan 29, 2026after close | $4.40 | $4.47 | +1.59% | +4.31% | +2.29% |
| Oct 30, 2025after close | $3.13 | $3.19 | +1.92% | -3.45% | -4.11% |
| Jul 31, 2025after close | $3.07 | $3.13 | +1.95% | -3.80% | -4.17% |
| May 1, 2025after close | $2.73 | $2.84 | +4.03% | +1.13% | +2.26% |
| Jan 28, 2025after close | $3.87 | $4.01 | +3.62% | -1.03% | -0.70% |
As of October 30, 2026, SYK has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 30, 2026, came in 5.73% above the estimate and the stock moved -6.42% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
SYK AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 48.0, in neutral territory.RSI below 50 ›
An RSI of 48.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of SYK
The score, the reasoning behind it, and what could move the price next.
Stryker Corp. (SYK) is trading at $291.86, below both of its main moving averages. The price sits 0.29% below its 50-day average of $292.71 and 9.87% below its 200-day average of $323.82. Within its 52-week range the stock is at 20%, 9.31% above the 52-week low of $267.00. Both averages point the same way, since the 50-day sits 9.61% below the 200-day.
Recent gains sit against a weaker longer record: the price rose 5.98% over the past month, fell 10.39% over the past three months and fell 20.90% over the past year. The price fell 6.38% in the last session on volume 118.7% above its average. On momentum, the 14-day RSI reads 48.0, in the neutral zone, with the MACD line positive.
New analyst coverage ›
Barclays started coverage at Overweight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026Rating reaffirmed ›
BTIG kept its Buy rating on October 12, 2026.
Source: Analyst action, BTIG, October 12, 2026
Earnings beat, but the stock fell ›
The July 30, 2026 report beat the EPS estimate by 5.73%, and the share price fell 6.42% in the first session after it.
Source: Earnings report, July 30, 2026
- The two nearest levels to watch are the 50-day SMA at $292.71, which sits above the price, and the 52-week low at $267.00, which sits below it.
- A 14-day RSI of 48.0 sits in the neutral zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- Following the July 30, 2026 report, the share price declined 6.42% in the first session. Over the last 7 reports, SYK beat estimates in 6 of them.
SYK remains in a downtrend while it trades under both its 50-day average of $292.71 and its 200-day average of $323.82. A close above the 50-day would mark the first sign of a repair, and that average at $292.71 is the first barrier the price would have to clear.
The next level below the price is the 52-week low at $267.00.
Technical indicators
Momentum and trend for SYK, from its daily closes.
As of October 30, 2026, with SYK at $291.86, its 14-day RSI is 48.0 (neutral territory), its 50-day simple moving average is $292.71 and its 200-day is $323.82.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What SYK moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, SYK's 1-year correlation of daily returns is +0.34 with S&P 500 (SPY), +0.19 with Nasdaq 100 (QQQ), -0.07 with Bitcoin (BTC) and +0.00 with gold (XAU).
SYK price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
23 of 29 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $360.00 is 23.3% above the price.No more buy ratings than three months ago ›
23 of 29 rate it a buy now, against 23 of 28 three months ago.
SYK Wall Street View
12-month price targets
The price, $291.86, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | BTIG | Maintains | Buy |
| Oct 7, 2026 | Truist Securities | Maintains | Hold |
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Sep 30, 2026 | Stifel | Maintains | Buy |
| Sep 22, 2026 | TD Cowen | Maintains | Hold |
| Sep 18, 2026 | Canaccord Genuity | Maintains | Buy |
As of October 30, 2026, 29 Wall Street analysts cover SYK: 23 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $298.00 to $465.00. The median SYK price target is $360.00, 23.3% above the price of $291.86.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
SYK trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
SYK trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from SYK's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much SYK tends to move, against the market and on its own.
SYK price history and drawdowns
SYK's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move of 2% or more ›
The price has moved 2.03% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 33.4%, from February 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
75% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $28,248, against $41,607 in the S&P 500 (SPY).
SYK Drawdowns & Recovery
As of October 30, 2026, SYK's worst peak-to-trough fall over the last 10 years with dividends reinvested was -33.4% (February 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 75% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into SYK in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: SYK trailed the S&P 500 over this period: $28,248 against $41,607.
A $10,000 investment in SYK in October 2016 would be worth about $28,248 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to SYK, and which have not.
Strongest month, January: an average of +4.56%, up in 9 of 10 years.
Weakest month, March: an average of -2.26%, up in 4 of 10 years.
This month, October: has averaged +1.41%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, SYK's strongest calendar month has been January (average +4.56%, up in 9 of 10 years) and its weakest March (average -2.26%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
SYK stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in SYK, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in SYK today could grow to about $13,430 by 2030 in the base case, with a 90th-percentile outcome near $26,953 and a 10th-percentile outcome around $6,692. The simulation models price only; at today's 1.21% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
SYK Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $392 for SYK by 2030 in the base case, from $292 today (1.3x over 4 years). The 10th-percentile path ends near $195. These are outcomes of a Monte Carlo simulation run on SYK's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $222 | $314 | $445 | |
| 2028 | $207 | $338 | $554 | |
| 2029 | $199 | $364 | $666 | |
| 2030 | $195 | $392 | $787 |
Method: a lognormal simulation of SYK's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
SYK insider trading
What the people running the company have bought and sold.
SYK insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought SYK shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, SYK insiders reported 16 open-market sales worth $738.2M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Dylan Bram Crotty
Officer
|
Sell | 441 | $144.9K |
| Aug 19, 2026 | Ronda E Stryker
Director
|
Sell | 350.0K | $117.8M |
| Aug 18, 2026 | Debra King
Officer
|
Sell | 826 | $277.8K |
| Jun 1, 2026 | Spencer S Stiles
President
|
Grant | 1.6K | - |
| May 28, 2026 | Robert S Fletcher
Officer
|
Sell | 4.5K | $1.4M |
| May 26, 2026 | Ronda E Stryker
Director
|
Sell | 310.0K | $96.8M |
| May 11, 2026 | Mary Kathryn Fink
Officer
|
Sell | 8.7K | $2.5M |
| May 8, 2026 | Mary Kathryn Fink
Officer
|
Option | 21.6K | $3.6M |
| May 6, 2026 | Mary K Brainerd
Director
|
Grant | 762 | - |
| May 6, 2026 | Giovanni Caforio
Director
|
Grant | 762 | - |
| May 6, 2026 | Debra King
Chief Technology Officer
|
Grant | 1.0K | - |
| May 6, 2026 | Emmanuel Perez Maceda
Director
|
Grant | 762 | - |
| May 6, 2026 | Sherilyn S Mccoy
Director
|
Grant | 762 | - |
| May 6, 2026 | Kimberly Ann Montagnino
Officer
|
Grant | 677 | - |
| May 6, 2026 | Rachel Ruggeri
Director
|
Grant | 762 | - |
| May 6, 2026 | Andrew K. Silvernail
Director
|
Grant | 762 | - |
| May 6, 2026 | Tatum Lisa M Skeete
Director
|
Grant | 762 | - |
| May 6, 2026 | Ronda E Stryker
Director
|
Grant | 762 | - |
| May 6, 2026 | Rajeev Suri
Director
|
Grant | 762 | - |
| Mar 20, 2026 | Mary Kathryn Fink
Officer
|
Grant | 150 | - |
| Mar 20, 2026 | Robert S Fletcher
Officer
|
Grant | 225 | - |
| Mar 20, 2026 | Kevin A Lobo
Chief Executive Officer
|
Grant | 1.5K | - |
| Mar 20, 2026 | Viju S Menon
Officer
|
Grant | 269 | - |
| Mar 20, 2026 | James Andrew Pierce
Officer
|
Grant | 430 | - |
| Mar 20, 2026 | Spencer S Stiles
President
|
Grant | 430 | - |
| Mar 9, 2026 | Mary Kathryn Fink
Officer
|
Grant | 5.2K | - |
| Mar 9, 2026 | Robert S Fletcher
Officer
|
Grant | 7.8K | - |
| Mar 9, 2026 | Kevin A Lobo
Chief Executive Officer
|
Grant | 50.3K | - |
| Mar 9, 2026 | Viju S Menon
Officer
|
Grant | 9.3K | - |
| Mar 9, 2026 | James Andrew Pierce
Officer
|
Grant | 14.9K | - |
| Mar 9, 2026 | Spencer S Stiles
President
|
Grant | 14.9K | - |
| Feb 23, 2026 | Ronda E Stryker
Director
|
Grant | 55.6K | - |
| Feb 17, 2026 | Ronda E Stryker
Director
|
Grant | 600.2K | - |
| Feb 6, 2026 | Kevin A Lobo
Chief Executive Officer
|
Option | 207.0K | $20.0M |
| Feb 5, 2026 | Ronda E Stryker
Director
|
Sell | 500.0K | $181.7M |
| Feb 4, 2026 | William E Berry Jr
Officer
|
Grant | 797 | - |
| Feb 4, 2026 | James Andrew Pierce
Officer
|
Grant | 2.8K | - |
| Feb 3, 2026 | Spencer S Stiles
President
|
Option | 13.8K | $1.3M |
| Feb 2, 2026 | James Andrew Pierce
Officer
|
Sell | 475 | $175.2K |
| Feb 2, 2026 | James Andrew Pierce
Officer
|
Option | 13.8K | $1.3M |
| Jan 15, 2026 | Andrew K. Silvernail
Director
|
Option | 4.6K | $441.6K |
| Jan 14, 2026 | Ronda E Stryker
Director
|
Option | 4.6K | $441.6K |
| Nov 21, 2025 | James Andrew Pierce
Officer
|
Grant | 211 | - |
| Nov 20, 2025 | Preston Wendell Wells
Chief Financial Officer
|
Sell | 165 | $60.4K |
| Nov 14, 2025 | William E Berry Jr
Officer
|
Sell | 2.0K | $713.8K |
| Nov 14, 2025 | William E Berry Jr
Officer
|
Option | 4.9K | $759.1K |
| Nov 6, 2025 | Ronda E Stryker
Director
|
Sell | 520.0K | $184.6M |
| Aug 25, 2025 | Viju S Menon
Officer
|
Sell | 500 | $195.3K |
| Aug 20, 2025 | Robert S Fletcher
Officer
|
Sell | 1.8K | $701.6K |
| Aug 6, 2025 | Ronda E Stryker
Director
|
Sell | 200.0K | $75.3M |
| Aug 5, 2025 | Mary Kathryn Fink
Officer
|
Grant | 917 | - |
| Aug 5, 2025 | Debra King
Chief Technology Officer
|
Grant | 6.6K | - |
| May 12, 2025 | William E Berry Jr
Officer
|
Sell | 1.2K | $482.2K |
| May 8, 2025 | Mary K Brainerd
Director
|
Grant | 560 | - |
| May 8, 2025 | Giovanni Caforio
Director
|
Grant | 560 | - |
| May 8, 2025 | Emmanuel Perez Maceda
Director
|
Grant | 560 | - |
| May 8, 2025 | Rachel Ruggeri
Director
|
Grant | 560 | - |
| May 8, 2025 | Andrew K. Silvernail
Director
|
Grant | 560 | - |
| May 8, 2025 | Tatum Lisa M Skeete
Director
|
Grant | 560 | - |
| May 8, 2025 | Ronda E Stryker
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 560 | - |
| May 8, 2025 | Rajeev Suri
Director
|
Grant | 560 | - |
| May 6, 2025 | Ronda E Stryker
Director and Beneficial Owner of more than 10% of a Class of Security
|
Sell | 200.0K | $75.4M |
Source: TwelveData, from SEC Form 4 filings
SYK stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.